13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $71M | -$343M | 0.0% | -512.9% | -$277M | — | $212M |
| 2024 | $302000 | -$270M | 0.0% | -99018.2% | -$233M | $21M | $100M |
| 2023 | $314000 | -$238M | 0.0% | -81035.0% | -$185M | $20M | $103M |
| 2022 | $2M | -$130M | 0.0% | -7579.2% | -$95M | $5M | $156M |
| 2021 | $3M | -$79M | 0.0% | -2690.8% | -$55M | $0 | $42M |
| 2020 | $1M | -$111M | 0.0% | -10512.4% | -$30M | — | $46M |
| 2019 | $4M | -$42M | 0.0% | -941.0% | -$36M | $8M | $25M |
| 2018 | $8M | -$33M | 0.0% | -394.5% | -$27M | $10M | $33M |
| 2017 | $4M | -$27M | 0.0% | -662.8% | -$28M | $10M | $47M |
| 2016 | — | -$17M | — | — | -$15M | — | — |
| 2015 | — | -$11M | — | — | -$7M | — | — |
| 2014 | — | -$8M | — | — | -$2M | — | — |
| 2013 | — | -$2M | — | — | -$1M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $141000 | -$105M | 0.0% | -82389.4% | -$120M | — | $176M |
| Dec '25 | $132000 | -$120M | 0.0% | -92991.7% | -$24M | — | $212M |
| Sep '25 | $71M | -$35M | 0.0% | -56.7% | -$85M | $21M | $170M |
| Jun '25 | $75000 | -$101M | 0.0% | -142356.0% | -$75M | $21M | $117M |
| Mar '25 | $72000 | -$87M | 0.0% | -130369.4% | -$93M | $21M | $116M |
| Dec '24 | $72000 | -$80M | 0.0% | -121488.9% | -$73M | $21M | $100M |
| Sep '24 | $86000 | -$77M | 0.0% | -97069.8% | -$68M | $21M | $200M |
| Jun '24 | $72000 | -$65M | 0.0% | -100259.7% | -$46M | $20M | $108M |
| Mar '24 | $72000 | -$49M | 0.0% | -77634.7% | -$45M | $20M | $92M |
| Dec '23 | $72000 | -$67M | 0.0% | -99275.0% | -$38M | $20M | $103M |
| Sep '23 | $72000 | -$48M | 0.0% | -71144.4% | -$39M | $20M | $112M |
| Jun '23 | $72000 | -$55M | 0.0% | -82326.4% | -$46M | $5M | $87M |
| Mar '23 | $98000 | -$68M | 0.0% | -73952.0% | -$62M | $5M | $89M |
| Dec '22 | $105000 | -$46M | 0.0% | -46729.5% | -$34M | $5M | $156M |
| Sep '22 | $1M | -$29M | 0.0% | -2492.5% | -$21M | $5M | $344M |
| Jun '22 | $256000 | -$29M | 0.0% | -11548.4% | -$18M | $5M | $31M |
| Mar '22 | $216000 | -$26M | 0.0% | -11985.6% | -$21M | — | $31M |
| Dec '21 | $214000 | -$29M | 0.0% | -13589.3% | -$17M | $0 | $42M |
| Sep '21 | $208000 | -$14M | 0.0% | -6795.2% | -$12M | — | $139M |
| Jun '21 | $1M | -$18M | 0.0% | -1651.2% | -$15M | — | $28M |
How the market has priced VRDN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Viridian Therapeutics, Inc.De's revenue has grown 132.2% per year. These are computed facts, not advice.
As of FY2025, Viridian Therapeutics, Inc.De reported — of total debt against $212M of cash; operating income covered interest expense -73.4×.
In FY2025, gross margin was —, operating margin -512.9%, and net margin -483.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.